PMID- 28624396
OWN - NLM
STAT- MEDLINE
DCOM- 20191017
LR  - 20240318
IS  - 1876-7591 (Electronic)
IS  - 1936-878X (Print)
IS  - 1876-7591 (Linking)
VI  - 11
IP  - 1
DP  - 2018 Jan
TI  - Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With 
      Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.
PG  - 94-107
LID - S1936-878X(17)30450-3 [pii]
LID - 10.1016/j.jcmg.2017.02.021 [doi]
AB  - OBJECTIVES: The purpose of this study was to explore the diagnostic usefulness of 
      hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) 
      using (18)F-fluorodeoxyglucose (FDG) for active cardiac sarcoidosis. BACKGROUND: 
      Active cardiac sarcoidosis (aCS) is underdiagnosed and has a high mortality. 
      METHODS: Patients with clinical suspicion of aCS underwent hybrid CMR/PET with 
      late gadolinium enhancement (LGE) and FDG to assess the pattern of injury and 
      disease activity, respectively. Patients were categorized visually as magnetic 
      resonance (MR)+PET+ (characteristic LGE aligning exactly with increased FDG 
      uptake), MR+PET- (characteristic LGE but no increased FDG), MR-PET- (neither 
      characteristic LGE nor increased FDG), and MR-PET+ (increased FDG uptake in 
      absence of characteristic LGE) and further characterized as aCS+ (MR+PET+) or 
      aCS- (MR+PET-, MR-PET-, MR-PET+). FDG uptake was quantified using maximum 
      target-to-normal-myocardium ratio and the net uptake rate (K(i)) from dynamic 
      Patlak analysis. Receiver-operating characteristic methods were used to identify 
      imaging biomarkers for aCS. FDG PET was assessed using computed tomography/PET in 
      19 control subjects with healthy myocardium. RESULTS: A total of 25 patients (12 
      males; 54.9 +/- 9.8 years of age) were recruited prospectively; 8 were MR+PET+, 
      suggestive of aCS; 1 was MR+PET-, consistent with inactive cardiac sarcoidosis; 
      and 8 were MR-PET-, with no imaging evidence of cardiac sarcoidosis. Eight 
      patients were MR-PET+ (6 with global myocardial FDG uptake, 2 with 
      focal-on-diffuse uptake); they demonstrated distinct K(i) values and hyperintense 
      maximum standardized uptake value compared with MR+PET+ patients. Similar 
      hyperintense patterns of global (n = 9) and focal-on-diffuse (n = 2) FDG uptake 
      were also observed in control patients, suggesting physiological myocardial 
      uptake. Maximum target-to-normal-myocardium ratio values were higher in the aCS+ 
      group (p < 0.001), demonstrating an area under the curve of 0.98 on 
      receiver-operating characteristic analysis for the detection of aCS, with an 
      optimal maximum target-to-normal myocardium ratio threshold of 1.2 (Youden index: 
      0.94). CONCLUSIONS: CMR/PET imaging holds major promise for the diagnosis of aCS, 
      providing incremental information about both the pattern of injury and disease 
      activity in a single scan. (In Vivo Molecular Imaging [MRI] of Atherothrombotic 
      Lesions; NCT01418313).
CI  - Copyright (c) 2018 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Dweck, Marc R
AU  - Dweck MR
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York; British Heart Foundation/University Centre for 
      Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United 
      Kingdom.
FAU - Abgral, Ronan
AU  - Abgral R
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York; Department of Nuclear Medicine, European University of 
      Brittany, CHRU Brest, Brest, France.
FAU - Trivieri, Maria Giovanna
AU  - Trivieri MG
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York.
FAU - Robson, Philip M
AU  - Robson PM
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York.
FAU - Karakatsanis, Nicolas
AU  - Karakatsanis N
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York.
FAU - Mani, Venkatesh
AU  - Mani V
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York.
FAU - Palmisano, Anna
AU  - Palmisano A
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York.
FAU - Miller, Marc A
AU  - Miller MA
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Lala, Anuradha
AU  - Lala A
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Chang, Helena L
AU  - Chang HL
AD  - International Center for Health Outcomes and Innovation Research, Department of 
      Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, 
      New York, New York.
FAU - Sanz, Javier
AU  - Sanz J
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Contreras, Johanna
AU  - Contreras J
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Narula, Jagat
AU  - Narula J
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Fuster, Valentin
AU  - Fuster V
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Padilla, Maria
AU  - Padilla M
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine 
      at Mount Sinai, New York, New York.
FAU - Fayad, Zahi A
AU  - Fayad ZA
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York. Electronic address: zahi.fayad@mssm.edu.
FAU - Kovacic, Jason C
AU  - Kovacic JC
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York. Electronic address: jason.kovacic@mountsinai.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT01418313
GR  - FS/14/78/31020/BHF_/British Heart Foundation/United Kingdom
GR  - R01 HL071021/HL/NHLBI NIH HHS/United States
GR  - R01 HL135878/HL/NHLBI NIH HHS/United States
GR  - T32 HL007824/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170614
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
CIN - JACC Cardiovasc Imaging. 2018 Jan;11(1):108-110. PMID: 28624409
MH  - Adult
MH  - Aged
MH  - Cardiomyopathies/*diagnostic imaging/drug therapy/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Fluorodeoxyglucose F18/*administration & dosage
MH  - Humans
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Positron Emission Tomography Computed Tomography
MH  - *Positron-Emission Tomography
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Radiopharmaceuticals/*administration & dosage
MH  - Reproducibility of Results
MH  - Sarcoidosis/*diagnostic imaging/drug therapy/pathology
MH  - Severity of Illness Index
PMC - PMC5995315
MID - NIHMS970804
OTO - NOTNLM
OT  - (18)F-fluorodeoxyglucose
OT  - MR/PET
OT  - cardiac sarcoidosis
EDAT- 2017/06/19 06:00
MHDA- 2019/10/18 06:00
PMCR- 2018/06/11
CRDT- 2017/06/19 06:00
PHST- 2016/11/28 00:00 [received]
PHST- 2017/01/31 00:00 [revised]
PHST- 2017/02/07 00:00 [accepted]
PHST- 2017/06/19 06:00 [pubmed]
PHST- 2019/10/18 06:00 [medline]
PHST- 2017/06/19 06:00 [entrez]
PHST- 2018/06/11 00:00 [pmc-release]
AID - S1936-878X(17)30450-3 [pii]
AID - 10.1016/j.jcmg.2017.02.021 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2018 Jan;11(1):94-107. doi: 10.1016/j.jcmg.2017.02.021. 
      Epub 2017 Jun 14.